Effect of bosentan on skin fibrosis in patients with systemic sclerosis: A prospective, open-label, non-comparative trial

Rheumatology

Volumn 49, Issue 7, 2010, Pages 1336-1345

  Kuhn, Annegret ^a   Haust, Merle ^b   Ruland, Vincent ^a   Weber, Ramona ^a   Verde, Pablo ^b   Felder, Gerd ^b   Ohmann, Christian ^b   Gensch, Kristina ^b   Ruzicka, Thomas ^c  

^a UNIVERSITY OF MÜNSTER   (Germany)

^b HEINRICH HEINE UNIVERSITY   (Germany)

^c LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

Author keywords

Bosentan; Clinical trial; Digital ulcers; Endothelin receptor antagonist; Skin fibrosis; Systemic sclerosis

Indexed keywords

AZATHIOPRINE; BOSENTAN; CORTICOSTEROID; NONSTEROID ANTIINFLAMMATORY AGENT;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; DIGITAL RADIOGRAPHY; DISABILITY; DISEASE ASSOCIATION; DIZZINESS; DRUG INDUCED HEADACHE; ECHOGRAPHY; ERECTILE DYSFUNCTION; FEMALE; FLUSHING; FUNCTIONAL ASSESSMENT; HAND FUNCTION; HUMAN; INFLUENZA; LEG EDEMA; LIVER FUNCTION TEST; MALE; MODIFIED RODNAN SKIN SCORE; NAUSEA; OPEN STUDY; PARESTHESIA; PRIORITY JOURNAL; SCORING SYSTEM; SIDE EFFECT; SKIN FIBROSIS; SKINFOLD; SYSTEMIC SCLEROSIS; TREATMENT DURATION; VISUAL ANALOG SCALE;

AGED; FEMALE; FIBROSIS; HUMANS; MALE; MIDDLE AGED; RECEPTORS, ENDOTHELIN; SCLERODERMA, SYSTEMIC; SKIN ULCER; STATISTICS AS TOPIC; SULFONAMIDES; TREATMENT OUTCOME;

EID: 77954186593     PISSN: 14620324     EISSN: 14620332     Source Type: Journal    
DOI: 10.1093/rheumatology/keq077     Document Type: Article

References (47)

1. Hunzelmann N, Genth E, Krieg T et al. The registry of the German Network for Systemic Scleroderma: frequency of disease subsets and patterns of organ involvement. Rheumatology 2008;47:1185-92.
2. Chifflot H, Fautrel B, Sordet C, Chatelus E, Sibilia J. Incidence and prevalence of systemic sclerosis: a systematic literature review. Semin Arthritis Rheum 2008; 37:223-35.
3. LeRoy EC, Black C, Fleischmajer R et al. Scleroderma (systemic sclerosis): classification, subsets and pathogenesis. J Rheumatol 1988;15:202-5.
4. Krieg T, Takehara K. Skin disease: a cardinal feature of systemic sclerosis. Rheumatology 2009;48(Suppl. 3): iii14-8.
5. Grassegger A, Pohla-Gubo G, Frauscher M, Hintner H. Autoantibodies in systemic sclerosis (scleroderma): clues for clinical evaluation, prognosis and pathogenesis. Wien Med Wochenschr 2008;158:19-28.
6. Biondi ML, Marasini B, Bassani C, Agastoni A. Increased plasma endothelin levels in patients with Raynaud's phenomenon. N Engl J Med 1991;324:1139-40.
7. Yamane K, Kashiwagi H, Suzuki N et al. Elevated plasma levels of endothelin-1 in systemic sclerosis. Arthritis Rheum 1991;34:243-4.
8. Mayes MD, Lacey JV Jr, Beebe-Dimmer J et al. Prevalence, incidence, survival, and disease characteristics of systemic sclerosis in a large US population. Arthritis Rheum 2003;48:2246-55.
9. Soldano S, Montagna P, Villaggio B et al. Endothelin and sex hormones modulate the fibronectin synthesis by cultured human skin scleroderma fibroblasts. Ann Rheum Dis 2009;68:599-602.
10. Kahaleh MB. Endothelin, an endothelial-dependent vasoconstrictor in scleroderma. Enhanced production and profibrotic action. Arthritis Rheum 1991;34:978-83.
11. Jeppsson A, Tazelaar HD, Miller VM, McGregor CG. Distribution of endothelin-1 in transplanted human lungs. Transplantation 1998;66:806-9.
12. Xu SW, Denton CP, Dashwood MR, Abraham DJ, Black CM. Endothelin-1 regulation of intercellular adhesion molecule-1 expression in normal and sclerodermal fibroblasts. J Cardiovasc Pharmacol 1998; 31(Suppl. 1):S545-7.
13. Knock GA, Terenghi G, Bunker CB, Bull HA, Dowd PM, Polak JM. Characterization of endothelin-binding sites in human skin and their regulation in primary Raynaud's phenomenon and systemic sclerosis. J Invest Dermatol 1993;101:73-8.
14. Vancheeswaran R, Magoulas T, Efrat G et al. Circulating endothelin-1 levels in systemic sclerosis subsets-a marker of fibrosis or vascular dysfunction? J Rheumatol 1994;21:1838-44.
15. Kawaguchi Y, Suzuki K, Hara M et al. Increased endothelin-1 production in fibroblasts derived from patients with systemic sclerosis. Ann Rheum Dis 1994;53: 506-10.
16. Clozel M, Fischli W, Guilly C. Specific binding of endothelin on human vascular smooth muscle cells in culture. J Clin Invest 1989;83:1758-61.
17. Rubin LJ, Roux S. Bosentan: a dual endothelin receptor antagonist. Expert Opin Investig Drugs 2002;11: 991-1002.
18. Denton CP, Pope JE, Peter HH et al. Long-term effects of bosentan on quality of life, survival, safety and tolerability in pulmonary arterial hypertension related to connective tissue diseases. Ann Rheum Dis 2008;67:1222-8.
19. Korn JH, Mayes M, Matucci Cerinic M et al. Digital ulcers in systemic sclerosis: prevention by treatment with bosentan, an oral endothelin receptor antagonist. Arthritis Rheum 2004;50:3985-93.
20. Seibold JR, Denton CP, Furst DE et al. Bosentan prevents occurrence but does not speed healing of digital ulcers in patients with systemic sclerosis (SSc) [abstract]. Arthritis Rheum 2005;52(Suppl. 9):552.
21. Selenko-Gebauer N, Duschek N, Minimair G, Stingl G, Karlhofer F. Successful treatment of patients with severe secondary Raynaud's phenomenon with the endothelin receptor antagonist bosentan. Rheumatology 2006; 45(Suppl. 3):iii45-8.
22. Hettema ME, Zhang D, Bootsma H, Kallenberg CG. Bosentan therapy for patients with severe Raynaud's phenomenon in systemic sclerosis. Ann Rheum Dis 2007; 66:1398-9.
23. Chamaillard M, Heliot-Hosten I, Constans J, Taieb A. Bosentan as a rescue therapy in scleroderma refractory digital ulcers. Arch Dermatol 2007;143:125-6.
24. Snyder MJ, Jacobs MR, Grau RG, Wilkes DS, Knox KS. Resolution of severe digital ulceration during a course of bosentan therapy. Ann Intern Med 2005;142:802-3.
25. Jain M, Varga J. Bosentan for the treatment of systemic sclerosis-associated pulmonary arterial hypertension, pulmonary fibrosis and digital ulcers. Expert Opin Pharmacother 2006;7:1487-501.
26. Riccardi MT, Chiala A, Lannone F, Grattagliano V, Covelli M, Lapadula G. [Treatment of digital ulcers in systemic sclerosis with endothelin-1 receptor antagonist (bosentan)]. Reumatismo 2007;59:135-9.
27. Tillon J, Herve F, Chevallier D, Muir JF, Levesque H, Marie I. Successful treatment of systemic sclerosis-related digital ulcers and sarcoidosis with endothelin receptor antagonist (bosentan) therapy. Br J Dermatol 2006;154: 1000-2.
28. Preliminary criteria for the classification of systemic sclerosis (scleroderma). Subcommittee for scleroderma criteria of the American Rheumatism Association Diagnostic and Therapeutic Criteria Committee. Arthritis Rheum 1980;23:581-90.
29. Clements PJ, Lachenbruch PA, Seibold JR et al. Skin thickness score in systemic sclerosis: an assessment of interobserver variability in 3 independent studies. J Rheumatol 1993;20:1892-6.
30. Matucci-Cerinic M, Seibold JR. Digital ulcers and outcomes assessment in scleroderma. Rheumatology 2008;47(Suppl. 5):v46-7.
31. Silman A, Akesson A, Newman J et al. Assessment of functional ability in patients with scleroderma: a proposed new disability assessment instrument. J Rheumatol 1998; 25:79-83.
32. Steen VD, Medsger TA Jr. The value of the health assessment questionnaire and special patient-generated scales to demonstrate change in systemic sclerosis patients over time. Arthritis Rheum 1997;40:1984-91.
33. Merkel PA, Herlyn K, Martin RW et al. Measuring disease activity and functional status in patients with scleroderma and Raynaud's phenomenon. Arthritis Rheum 2002;46: 2410-20.
34. Takehara K. Treatment of early diffuse cutaneous systemic sclerosis patients in Japan by low-dose corticosteroids for skin involvement. Clin Exp Rheumatol 2004;22:S87-9.
35. Moore TL, Lunt M, McManus B, Anderson ME, Herrick AL. Seventeen-point dermal ultrasound scoring system-a reliable measure of skin thickness in patients with systemic sclerosis. Rheumatology 2003;42:1559-63.
36. Akesson A, Hesselstrand R, Scheja A, Wildt M. Longitudinal development of skin involvement and reliability of high frequency ultrasound in systemic sclerosis. Ann Rheum Dis 2004;63:791-6.
37. Denton CP, Black CM, Abraham DJ. Mechanisms and consequences of fibrosis in systemic sclerosis. Nat Clin Pract Rheumatol 2006;2:134-44.
38. Vancheeswaran R, Azam A, Black C, Dashwood MR. Localization of endothelin-1 and its binding sites in scleroderma skin. J Rheumatol 1994;21:1268-76.
39. Khanna D, Merkel PA. Outcome measures in systemic sclerosis: an update on instruments and current research. Curr Rheumatol Rep 2007;9:151-7.
40. Furst DE, Clements PJ, Steen VD et al. The modified Rodnan skin score is an accurate reflection of skin biopsy thickness in systemic sclerosis. J Rheumatol 1998;25:84-8.
41. Kaldas M, Khanna PP, Furst DE et al. Sensitivity to change of the modified Rodnan skin score in diffuse systemic sclerosis-assessment of individual body sites in two large randomized controlled trials. Rheumatology 2009; 48:1143-6.
42. Ferri C, Valentini G, Cozzi F et al. Systemic sclerosis: demographic, clinical, and serologic features and survival in 1012 Italian patients. Medicine 2002;81:139-53.
43. Colglazier CL, Sutej PG, O'Rourke KS. Severe refractory fingertip ulcerations in a patient with scleroderma: successful treatment with sildenafil. J Rheumatol 2005;32: 2440-2.
44. Gore J, Silver R. Oral sildenafil for the treatment of Raynaud's phenomenon and digital ulcers secondary to systemic sclerosis. Ann Rheum Dis 2005;64:1387.
45. Funauchi M, Kishimoto K, Shimazu H et al. Effects of bosentan on the skin lesions: an observational study from a single center in Japan. Rheumatol Int 2009;29: 769-75.
46. Tsifetaki N, Botzoris V, Alamanos Y, Argyriou E, Zioga A, Drosos AA. Bosentan for digital ulcers in patients with systemic sclerosis: a prospective 3-year followup study. J Rheumatol 2009;36:1550-2.
47. Ferreira ME, Scheinberg MA. Successful treatment with bosentan of non-digital skin ulcers in severe scleroderma. Ann Rheum Dis 2008;67:1784-5.